[HTML][HTML] Phase 1 LymfactinⓇ Study: short-term safety of combined adenoviral VEGF-C and lymph node transfer treatment for upper extremity lymphedema
P Hartiala, S Suominen, E Suominen… - Journal of Plastic …, 2020 - Elsevier
Objective To study the safety and tolerability of LymfactinⓇ treatment combined with
microvascular lymph node transfer surgery in patients with upper limb lymphedema.
Background Upper limb lymphedema is a common clinical challenge after breast cancer
surgery and/or radiotherapy. LymfactinⓇ is an adenovirus type 5–based gene therapy
involving expression of human vascular endothelial growth factor C (VEGF-C) in the
damaged tissue. It aims to correct deficient lymphatic flow by promoting the growth and …
microvascular lymph node transfer surgery in patients with upper limb lymphedema.
Background Upper limb lymphedema is a common clinical challenge after breast cancer
surgery and/or radiotherapy. LymfactinⓇ is an adenovirus type 5–based gene therapy
involving expression of human vascular endothelial growth factor C (VEGF-C) in the
damaged tissue. It aims to correct deficient lymphatic flow by promoting the growth and …